Medical Cannabis and Mental Health UK

Mental health conditions are among the most common reasons UK patients seek a private medical cannabis prescription. Anxiety disorders, PTSD, and depression feature prominently in prescription data. However, the relationship between cannabis and mental health is more nuanced than for purely physical conditions — and it is essential that patients have an accurate, balanced picture before making treatment decisions.

What Conditions May Qualify

Anxiety Disorders

Generalised anxiety disorder (GAD), social anxiety disorder, and panic disorder are among the anxiety conditions for which UK clinics routinely prescribe. The evidence base is meaningful: CBD has established anxiolytic properties and does not carry the anxiety-inducing risk that high doses of THC can present. Clinical data suggest that CBD-dominant or balanced formulations can reduce anxiety symptoms in patients who have not responded adequately to standard treatments — typically SSRIs, SNRIs, or CBT. See our anxiety condition guide for more detail.

PTSD

Post-traumatic stress disorder has among the strongest evidence bases of any mental health condition for medical cannabis. The endocannabinoid system is involved in fear memory extinction — the process by which traumatic memories lose their intensity — and cannabinoids appear to facilitate this process. UK data from Project Twenty21 included PTSD patients and showed meaningful improvements in quality of life and sleep scores. International evidence from Canada and Israel is more extensive and broadly positive. See our dedicated PTSD condition guide for more detail.

Treatment-Resistant Depression

Depression as a standalone primary indication is less commonly prescribed for in the UK than anxiety or PTSD. Treatment-resistant depression presenting alongside other qualifying conditions — chronic pain, anxiety, PTSD — may be considered. The evidence for cannabis as a primary antidepressant is limited and mixed; CBD may have some mood-modulating effects, but this is not an established primary indication at UK clinics.

ADHD

Some patients report symptomatic benefit from cannabis for ADHD, particularly for associated anxiety and sleep difficulties. A small number of UK clinics will consider ADHD as a qualifying condition. The evidence base is limited and the clinical approach varies significantly between providers.

What Does Not Qualify — Conditions Where Cannabis Is Contraindicated

This section is critical. Cannabis is not appropriate for all mental health patients, and prescribing to unsuitable candidates can cause serious harm.

Psychosis and Schizophrenia Spectrum Disorders

Active psychosis is an absolute contraindication to THC-containing cannabis products. THC can trigger acute psychotic episodes, worsen existing psychotic symptoms, and accelerate the clinical course of schizophrenia spectrum conditions. Even in patients with a personal or family history of psychosis, THC carries significantly elevated risk. The association between high-potency cannabis and first-episode psychosis is one of the most well-established findings in psychiatric epidemiology. UK clinics conduct mandatory screening for personal and family history of psychosis before prescribing. No reputable UK clinic will prescribe THC-containing products to a patient with active psychosis.

Bipolar Disorder and Medical Cannabis in the UK

Bipolar disorder is one of the more complex areas in medical cannabis prescribing, and the evidence is genuinely mixed. Unlike anxiety or PTSD — where there is a relatively clear direction of benefit — bipolar disorder presents specific risks alongside potential benefits, and UK clinics vary significantly in their approach.

Where some patients report benefit: Patients with bipolar II disorder (characterised by hypomania rather than full mania) who have primarily depressive episodes sometimes report that CBD-dominant formulations improve sleep, reduce anxiety, and stabilise low mood. The sleep-modulating effects of cannabis-based medicines may be particularly relevant in bipolar disorder, where disrupted sleep is both a symptom and a trigger for mood episodes.

Significant risks to understand: THC can precipitate or worsen manic and hypomanic episodes in some patients with bipolar disorder. Even in patients who have not previously experienced psychosis, high-THC products carry an elevated risk of mood destabilisation in this population. Historically, recreational cannabis use is associated with worse outcomes in bipolar disorder — though medicinal prescribing, typically at lower and more controlled doses, may present a different risk profile.

Drug interactions: Most patients with bipolar disorder are on mood stabilisers (lithium, valproate, lamotrigine) or antipsychotics. CBD is metabolised via CYP3A4 and CYP2C19 — the same pathways as some mood stabilisers — meaning drug-level monitoring may be required. Your prescribing specialist must review all current psychiatric medications before prescribing.

UK clinic approaches: A minority of UK cannabis clinics will consider bipolar disorder patients on an individual basis, generally where: the patient has bipolar II (not bipolar I); mood is currently stable and well-documented; they are under active psychiatric care; and conventional options have been inadequate. Most clinics will not prescribe for bipolar I disorder as a primary indication. If you have bipolar disorder and are considering medical cannabis, contact individual clinics directly and be transparent about your diagnosis and current treatment — this allows an honest eligibility assessment.

Active Substance Use Disorders

A history of cannabis use disorder requires careful clinical evaluation. It does not automatically disqualify a patient, but responsible prescribers will consider this carefully. Active heavy recreational cannabis use alongside a medical prescription is not appropriate and should be disclosed at consultation.

CBD vs THC for Mental Health

For mental health conditions specifically, the distinction between CBD and THC is more clinically significant than for many physical conditions:

• CBD: Non-psychoactive, anxiolytic at therapeutic doses, does not trigger psychosis or paranoia, good safety profile. CBD-dominant formulations are preferred for most mental health prescriptions.
• THC: Psychoactive, sleep-modulating — but at higher doses can cause or worsen anxiety, paranoia, and dissociation. High-THC products are used cautiously in mental health; dosing is typically started very low and titrated slowly.

Most UK mental health prescriptions involve CBD-dominant (high CBD:THC ratio) or balanced (1:1) formulations, with high-THC products reserved for specific presentations such as night-time PTSD symptom management under careful clinical monitoring.

UK Prescribing Practice and Monitoring

UK clinics prescribing for mental health conditions are expected to conduct a full psychiatric screening at initial consultation (including personal and family history of psychosis, bipolar disorder, substance use); start at low doses and titrate upward slowly; schedule follow-up appointments more frequently initially; monitor for adverse mental health outcomes; and discontinue or adjust if adverse effects emerge. If you are prescribed medical cannabis for a mental health condition, keep detailed notes of your symptoms and share them honestly at follow-up appointments.

Mental Health Conditions and Evidence Summary — UK 2026

Accessing Treatment

The process for accessing medical cannabis for a mental health condition is the same as for physical conditions — an initial video consultation with a GMC-registered specialist, a review of your medical history, and, if appropriate, a prescription. Costs range from £79 to £299 for an initial consultation. For a step-by-step overview, see our consultation guide and our NHS vs private guide.

For mental health conditions specifically, consider clinics with documented depth of experience in psychiatric presentations. Mamedica and TMCC both have strong records in PTSD and anxiety; Releaf covers anxiety and ADHD via their digital-first model. See the full clinic comparison for current fees and waiting times.

Frequently Asked Questions